{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/melanoma-pigmented-lesions/management/management/","result":{"pageContext":{"chapter":{"id":"01c409db-6041-5f5d-8faf-ad2b86d6a736","slug":"management","fullItemName":"Scenario: Management","depth":2,"htmlHeader":"<!-- begin field 475469f6-b3ad-4d6d-a3cd-25d025e3f69e --><h2>Scenario: Management</h2><!-- end field 475469f6-b3ad-4d6d-a3cd-25d025e3f69e -->","summary":"Covers the management of pigmented lesions in primary care, including referral of suspected melanoma. It also covers advice on the prevention of malignant melanoma and self-care advice to people at increased risk of developing melanoma.","htmlStringContent":"<!-- begin item 917c5e9f-ba6e-4c86-86db-394c4599fe48 --><!-- begin field 877d32b6-a071-4c8a-b172-acbc015859f9 --><p>From age 1 month onwards.</p><!-- end field 877d32b6-a071-4c8a-b172-acbc015859f9 --><!-- end item 917c5e9f-ba6e-4c86-86db-394c4599fe48 -->","topic":{"id":"f5efb7d1-47fd-5e6a-a34d-95395f7523a0","topicId":"c296c560-d236-46ad-abcc-52c1fc0a1abf","topicName":"Melanoma and pigmented lesions","slug":"melanoma-pigmented-lesions","lastRevised":"Last revised in March 2017","chapters":[{"id":"6f710641-b9e2-5edc-aeed-890a7095cd96","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"88e3acd7-3799-5638-93fc-4739079b0f26","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"4cd2dca8-d311-5805-aea1-3870f6f4fccd","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"4b752af4-f177-5a66-a15f-20135ef4c005","slug":"changes","fullItemName":"Changes"},{"id":"a75a8fa4-d7d6-5932-b9a5-1d5af0bc564e","slug":"update","fullItemName":"Update"}]},{"id":"37450e93-1f0f-5e02-8d33-091798b27dd1","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"37acfb65-9e83-5bb2-b261-3d35d43dc478","slug":"goals","fullItemName":"Goals"},{"id":"c2f69e41-ef64-5440-97db-a9d74ccdb90f","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"d7224a15-69f9-5519-a181-db44131ecc01","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"5489c4c1-2dd5-5679-9dc8-3b4c8136dcb7","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"c5779c9e-ebcd-5682-9817-797e8b88a2f6","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"0f3ef819-faeb-58c1-b3a8-029ddf2d2ec2","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"97595147-c6d8-569e-8edd-b38e54974224","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"b87206e4-fbe6-5ff3-b4db-757e2bdce473","slug":"definition","fullItemName":"Definition"},{"id":"7f5895c0-5070-5a7b-b402-836e18bde1fb","slug":"features","fullItemName":"Features"},{"id":"28380e7d-9dea-5a1f-9be7-1d7ac0e5a123","slug":"risk-factors","fullItemName":"Risk factors"},{"id":"7f9731f8-f8a0-5020-95ad-4220ee1b085a","slug":"prevalence","fullItemName":"Prevalence"},{"id":"fa22327f-becb-5e32-803b-7ff99e765cd1","slug":"prognosis","fullItemName":"Prognosis"},{"id":"ed48057f-9e82-56c6-8846-040b30894b15","slug":"non-melanotic-lesions","fullItemName":"Non-melanotic lesions"},{"id":"aaaf9edb-2903-5b78-831c-b7839586fdfe","slug":"other-pigmented-lesions","fullItemName":"Other pigmented lesions"}]},{"id":"5b41a523-ea89-5f11-bbd5-21118fe0f7b2","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"2a182f91-5ece-564a-a4e3-83ea99005110","slug":"assessment","fullItemName":"Assessment"},{"id":"bb757fc9-32cf-5a88-b59d-3b676b8fe2f0","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"},{"id":"260b59e0-5f81-5189-b2b1-781e2a96257a","slug":"biopsy-of-the-lesion","fullItemName":"Biopsy of the lesion"}]},{"id":"2a84a2c2-8b7a-582d-9ab2-4a4d23728f10","fullItemName":"Management","slug":"management","subChapters":[{"id":"01c409db-6041-5f5d-8faf-ad2b86d6a736","slug":"management","fullItemName":"Scenario: Management"}]},{"id":"b70563d4-10f0-517e-ab86-50e2e260e966","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[{"id":"84e1f7c4-66db-59e5-b9a9-1fc097979aa4","slug":"evidence-on-the-abcd-7-point-checklists","fullItemName":"Evidence on the ABCD and 7-point checklists"},{"id":"68448720-3dbd-530e-bf51-0c8d618ee81e","slug":"evidence-on-self-examination-for-early-melanoma-detection","fullItemName":"Evidence on self-examination for early melanoma detection"}]},{"id":"560a3b23-0b91-5538-a7e7-2b8d61f1dfed","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"9e328671-9080-5494-aeca-8cca3a845389","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"7968cb4d-c0a4-51ae-bc15-16ce3025ca18","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"f3daadc2-eacf-5bcf-8acb-473fa56481df","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"47ede055-d8df-5c65-8d5e-4189da7ac034","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"d2c30ae3-8839-58ef-8a53-f015bff32373","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"02f003b7-53e6-52fe-8c98-bc5580019357","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"2a84a2c2-8b7a-582d-9ab2-4a4d23728f10","slug":"management","fullItemName":"Management"},"subChapters":[{"id":"9abc4871-d546-573e-919c-8b2b1e87f096","slug":"referral","fullItemName":"Referral","depth":3,"htmlHeader":"<!-- begin field 2353cd4f-62bc-4024-93cd-ef9240399562 --><h3>When should I refer?</h3><!-- end field 2353cd4f-62bc-4024-93cd-ef9240399562 -->","summary":null,"htmlStringContent":"<!-- begin item 866befcc-f3ed-470c-a321-d5dae2617180 --><!-- begin field 1b5f34c4-27eb-40aa-b3b8-e937628d23ed --><ul><li><strong>Urgently refer (within 2 weeks) to a dermatologist, plastic surgeon, or other suitable specialist with experience of melanoma diagnosis </strong><strong>if:</strong><ul><li>The lesion is suggestive of malignant melanoma (including nodular and amelanotic melanoma). For example:<ul><li>Lesions scoring 3 points or more (based on major features scoring 2 points each and minor features scoring 1 point each) on the 7-point checklist. However, any one feature is adequate to prompt urgent referral.</li><li>New nodules which are pigmented or vascular in appearance.</li><li>Nail changes, such as a new pigmented line in the nail or pigmentation under the nail.</li></ul></li><li>There is any doubt about the lesion.</li><li>A skin condition is persistent or slowly evolving and unresponsive, with an uncertain diagnosis, and melanoma is a possibility.</li><li>A biopsy has confirmed the diagnosis of malignant melanoma. Note: if a lesion is suspected to be melanoma, an urgent referral to a dermatologist or other suitable specialist with experience of melanoma diagnosis should be made, and excision in primary care should be avoided.<ul><li>A copy of the pathology report should be sent with the referral correspondence, as there may be details (such as tumour thickness, excision margin) that will specifically influence further management.</li></ul></li></ul></li><li><strong>Routinely refer </strong><strong>for risk estimation, education and possible follow up in secondary care (although resources for follow up may be limited) </strong>if people are at higher risk (around 10-fold) of melanoma, such as those with:<ul><li>Giant congenital pigmented naevi (risk is highest for those measuring 20 cm in diameter or more).</li><li>A family history of 3 or more cases of melanoma — refer to a clinical geneticist or specialized dermatology service for counselling. Those with two cases in the family may also benefit, especially if one of the cases had multiple primary melanomas or the atypical mole phenotype.</li><li>More than 100 normal moles.</li><li>Atypical moles (particularly if multiple).</li></ul></li><li><strong>Referral is <em>not </em>usually required for obviously benign lesions, such as moles and seborrhoeic keratoses. </strong>Features which are generally reassuring and suggest a benign lesion include:<ul><li>Regularity of colour, surface, and border (suggests a benign lesion, such as a mole).</li><li>Rapid growth over days rather than weeks (suggests an underlying pyogenic granuloma rather than malignant change).</li><li>'Stuck on' appearance with keratotic plugs on the surface (suggests a seborrhoeic keratosis).</li><li>Dimpling if bilateral pressure is applied to the lesion (suggests a dermatofibroma).</li><li>A pigmented lesion in a child (melanoma is very rare in this age group).</li></ul></li></ul><!-- end field 1b5f34c4-27eb-40aa-b3b8-e937628d23ed --><!-- end item 866befcc-f3ed-470c-a321-d5dae2617180 -->","subChapters":[{"id":"d15205c8-885b-5b6c-bf48-29c9dbb6dbd4","slug":"information-to-include-with-referral","fullItemName":"Information to include with referral","depth":4,"htmlHeader":"<!-- begin field 44f15b65-f86d-4acf-9087-69fda4081a4a --><h4>What information should I include with referral?</h4><!-- end field 44f15b65-f86d-4acf-9087-69fda4081a4a -->","summary":null,"htmlStringContent":"<!-- begin item c6af4427-ee3c-4913-82b6-72895f452ed5 --><!-- begin field b033bf88-e7a5-43c6-933b-bf3e50572b1f --><ul><li><strong>Most regions will have a local referral form for pigmented lesions which should be used, if available. </strong>If not, include the following information:<ul><li>Location.</li><li>Size of lesion.</li><li>Shape.</li><li>Colour.</li><li>How long the lesion has been present.</li><li>Changes.</li><li>Symptoms (inflammation, oozing, crusting, bleeding, change in sensation).</li><li>Palpable lymph nodes.</li><li>Risk factors for melanoma.</li></ul></li></ul><!-- end field b033bf88-e7a5-43c6-933b-bf3e50572b1f --><!-- end item c6af4427-ee3c-4913-82b6-72895f452ed5 -->","subChapters":[]},{"id":"52ff20a0-a411-539b-b432-062402282cf2","slug":"basis-for-recommendation-040","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field 75531fb7-7de2-428a-97c9-cd198a3fd6c3 --><h4>Basis for recommendation</h4><!-- end field 75531fb7-7de2-428a-97c9-cd198a3fd6c3 -->","summary":null,"htmlStringContent":"<!-- begin item 04028770-876a-4cf9-a82f-0cb4df9e17ca --><!-- begin field 37d6ee35-0803-4bdb-a969-763ba215acad --><h5>Urgent referral (within 2 weeks)</h5><ul><li>This recommendation is based on expert opinion in guidelines from the National Institute for Health and Care Excellence on <em>Improving outcomes for people with skin tumours including melanoma </em>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/melanoma-pigmented-lesions/references/\">NICE, 2006</a>] <em> </em>and <em>Suspected cancer: recognition and </em>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/melanoma-pigmented-lesions/references/\">NICE, 2015a</a>] <em>and the paper Melanoma published by </em>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/melanoma-pigmented-lesions/references/\">BMJ Best Practice, 2017a</a>]. </li></ul><h5>Referral of someone at increased risk of melanoma</h5><ul><li>This recommendation is based on UK guidelines on <em>Prevention, Diagnosis, Referral, and Management of Melanoma of the Skin </em>and <em>Management of Cutaneous Melanoma </em>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/melanoma-pigmented-lesions/references/\">Marsden et al, 2010</a>].</li><li>Baseline photography should be used for melanocytic lesions which do not need excision [<a class=\"bibliography-reference internal-reference\" href=\"/topics/melanoma-pigmented-lesions/references/\">Macbeth, 2015</a>]. </li></ul><h5>Reassuring features</h5><ul><li>This recommendation is based on expert opinion in  [<a class=\"bibliography-reference internal-reference\" href=\"/topics/melanoma-pigmented-lesions/references/\">BMJ Best Practice, 2017a</a>].</li></ul><h5>Information to include with the referral</h5><ul><li>The recommendation on what information to include with a referral is based on expert opinion in guidelines from the National Institute for Health and Clinical Excellence on <em>Improving outcomes for people with skin tumours including melanoma </em>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/melanoma-pigmented-lesions/references/\">NICE, 2006</a>]</li></ul><!-- end field 37d6ee35-0803-4bdb-a969-763ba215acad --><!-- end item 04028770-876a-4cf9-a82f-0cb4df9e17ca -->","subChapters":[]}]},{"id":"d57bb90d-f6d2-51d2-af81-91cfe21d7f19","slug":"people-at-increased-risk-of-melanoma","fullItemName":"People at increased risk of melanoma","depth":3,"htmlHeader":"<!-- begin field e424e50a-384c-43d9-ba01-2cefa0eacdf0 --><h3>How should I manage people who are at increased risk of melanoma?</h3><!-- end field e424e50a-384c-43d9-ba01-2cefa0eacdf0 -->","summary":null,"htmlStringContent":"<!-- begin item 0f01ceac-5ada-4c72-ad6a-4365450eec70 --><!-- begin field 8328677c-2610-439d-af50-4289222ac822 --><ul><li><strong>For all people at increased risk of melanoma </strong>(for example people with freckles, red hair, or skin which burns in the sun; those with a previous melanoma or family history of skin cancer; people with more than 50 moles; and immunosuppressed people):<ul><li>Advise on <a class=\"topic-reference internal-reference\" href=\"/topics/melanoma-pigmented-lesions/management/management/#prevention-detection-of-skin-cancers\">prevention of skin cancer</a>. (See Skin Cancer Foundation)</li><li>Encourage them to perform monthly self-examinations. For more information, see the American Academy of Dermatology website: <a href=\"http://www.aad.org/public/exams/self.html\" data-hyperlink-id=\"b4fc6fde-e535-41a1-a953-a98d00651750\">www.aad.org/public/exams/self.html</a>.</li><li>Give information on signs and symptoms of suspicious lesions when to access medical advice.</li><li>Advise people who have had one type of skin cancer that they may develop a new and different lesion.</li></ul></li><li><strong>For people at higher risk of melanoma </strong>(for example those with a giant congenital pigmented naevus, a strong family history, atypical moles, or more than 100 normal moles), offer advice as above and explain that long-term follow up is recommended (usually with a dermatologist).</li></ul><!-- end field 8328677c-2610-439d-af50-4289222ac822 --><!-- end item 0f01ceac-5ada-4c72-ad6a-4365450eec70 -->","subChapters":[{"id":"070b7002-ad05-5ad3-947d-501058447fc6","slug":"basis-for-recommendation-297","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field c2151986-5dbf-4f04-b6b0-75302e4676c7 --><h4>Basis for recommendation</h4><!-- end field c2151986-5dbf-4f04-b6b0-75302e4676c7 -->","summary":null,"htmlStringContent":"<!-- begin item 2970268b-11a2-4453-9cea-4e6aa5a68edf --><!-- begin field 10aa1a65-e09c-4e1a-b28b-49ee6a933476 --><p>This recommendation is based on evidence from non-experimental studies in UK guidelines on the <em>Management of cutaneous melanoma </em>from the British Association of Dermatologists [<a class=\"bibliography-reference internal-reference\" href=\"/topics/melanoma-pigmented-lesions/references/\">Marsden et al, 2010</a>], UK guidelines from the National Institute for Health and Care Excellence on <em>Improving outcomes for people with skin tumours including melanoma </em>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/melanoma-pigmented-lesions/references/\">NICE, 2006</a>], <em>Skin cancer prevention </em>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/melanoma-pigmented-lesions/references/\">NICE, 2011</a>] and SIGN guidelines [<a class=\"bibliography-reference internal-reference\" href=\"/topics/melanoma-pigmented-lesions/references/\">SIGN, 2017</a>].</p><!-- end field 10aa1a65-e09c-4e1a-b28b-49ee6a933476 --><!-- end item 2970268b-11a2-4453-9cea-4e6aa5a68edf -->","subChapters":[]}]},{"id":"e3e5f323-341a-587d-a03d-ec07da244a01","slug":"prevention-detection-of-skin-cancers","fullItemName":"Prevention and detection of skin cancers","depth":3,"htmlHeader":"<!-- begin field 5aa7989d-4f63-4fae-8fd7-2c57fa55d550 --><h3>What advice should I give on prevention and detection of skin cancers?</h3><!-- end field 5aa7989d-4f63-4fae-8fd7-2c57fa55d550 -->","summary":null,"htmlStringContent":"<!-- begin item 6b16dc21-fd97-4af8-b693-7e80dd8ecbf3 --><!-- begin field cb84b124-de00-4827-9b21-e280d502afbd --><ul><li><strong>Advise the person that enjoying the sun safely (avoiding burning) can provide the benefits of vitamin D without raising the risk of skin cancer.</strong><ul><li>Although excessive sun exposure is the main cause of skin cancer, including melanoma, sun exposure is also the main source of vitamin D. Lack of vitamin D can cause such conditions as rickets and osteomalacia. It is important to balance the benefits of sun exposure with the person's risk of skin cancer, bearing in mind that the time to make sufficient vitamin D is typically less than the time taken to burn. For further information please refer to the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/vitamin-d-deficiency-in-adults-treatment-prevention/\">Vitamin D deficiency in adults - treatment and prevention</a>.</li></ul></li><li><strong>Give general advice to those at risk of skin cancer</strong><strong> to avoid excessive sun and ultraviolet (UV) exposure by:</strong><ul><li>Avoiding sunburn.</li><li>Using clothing to protect against the summer sun.</li><li>Using a broad-spectrum sunscreen (minimum sun protection factor [SPF] of 15 [only sufficient if applied adequately], but preferably SPF 20–30, with 4- or 5-star UVA protection), provided this does not lead to increased time spent in the sun. Use a water-resistant product if sweating or contact with water is likely.<ul><li>Sunscreen should be applied liberally half an hour before going out, and then reapplied after half an hour and then every 2 hours to ensure protection is adequate. On average, an adult needs around 35 millilitres (2 tablespoons) of sunscreen to cover the whole body. Sunscreen should also be reapplied after being in the water (even if it is labelled 'water resistant') and after towel drying.</li></ul></li><li>Avoiding direct, intense sunlight, and finding shade, especially between 11 am and 3 pm.</li><li>Using these measures not only when abroad in hot climates, but also in the summer in the UK, and when on winter sports holidays.</li><li>Avoiding tanning booths, tanning, lamps, and sunbeds.</li></ul></li><li><strong>In addition to general advice on sun and UV exposure, tailor advice to specific groups of people:</strong><ul><li><strong>Children </strong>— protect them with shade, clothing, and SPF 50+ sunscreen. Keep babies out of direct sunlight.</li><li><strong>Outdoor workers </strong>— protect exposed skin in the summer with regular (2-hourly) applications of high-protection sunscreen. Wear a hat that shades the face, neck, and ears. If possible, avoid the sun from 11 am to 3 pm and take breaks in the shade.</li></ul></li><li><strong>Advise people to seek medical advice if they have a mole which is:</strong><ul><li>Getting bigger.</li><li>Changing shape — particularly if the edge is becoming irregular.</li><li>Changing colour — getting darker, becoming patchy, or multi-shaded.</li><li>Persistently itchy or painful.</li><li>Bleeding or becoming crusty.</li><li>Inflamed and not settling.</li></ul></li><li>For further information, people can access the Cancer Research SunSmart campaign at <a href=\"http://www.sunsmart.org.uk/\" data-hyperlink-id=\"b95f1dfa-ba02-4529-b7eb-a9930060af77\">www.sunsmart.org.uk</a>. This provides information on many issues, including sunscreens, sunburn, moles and skin cancer, vitamin D, and winter sports.</li></ul><!-- end field cb84b124-de00-4827-9b21-e280d502afbd --><!-- end item 6b16dc21-fd97-4af8-b693-7e80dd8ecbf3 -->","subChapters":[{"id":"383caeff-19bc-5702-bf44-67b155c409c4","slug":"basis-for-recommendation-8d7","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field 0f9155ac-0b7c-4eff-9b17-7f3cf4fc10c2 --><h4>Basis for recommendation</h4><!-- end field 0f9155ac-0b7c-4eff-9b17-7f3cf4fc10c2 -->","summary":null,"htmlStringContent":"<!-- begin item 8d74c016-5481-4b29-8ccc-dc49ea8032fb --><!-- begin field e6482c8c-6e83-4aff-92ef-047afae607a4 --><h5>Vitamin D deficiency</h5><ul><li>This information is based on a consensus vitamin D position statement from NICE and Cancer Research UK [<a class=\"bibliography-reference internal-reference\" href=\"/topics/melanoma-pigmented-lesions/references/\">NICE, 2014</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/melanoma-pigmented-lesions/references/\">Cancer Research UK, 2016b</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/melanoma-pigmented-lesions/references/\">BMJ Best Practice, 2017a</a>].</li></ul><h5>Advice on the prevention of skin cancers</h5><ul><li>These recommendations are based on expert opinion in guidelines from the National Institute for Health and Care Excellence on <em>Improving outcomes for people with skin cancer including melanoma </em>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/melanoma-pigmented-lesions/references/\">NICE, 2006</a>] and <em>Skin cancer prevention </em>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/melanoma-pigmented-lesions/references/\">NICE, 2016b</a>], evidence from randomized controlled trials in guidelines from the Royal College of Physicians and the British Association of Dermatologists on the <em>Prevention, diagnosis, referral, and management of melanoma of the skin </em>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/melanoma-pigmented-lesions/references/\">Marsden et al, 2010</a>].</li><li>People should be advised to avoid sun beds as the risk of melanoma increases with the number of sunbed sessions, especially if initiated at under 35 years of age [<a class=\"bibliography-reference internal-reference\" href=\"/topics/melanoma-pigmented-lesions/references/\">Boniol, 2012</a>]. </li><li>There is a difference in opinion between expert organizations in relation to the recommended sun protection factor (SPF) that should be used. The Royal College of Physicians and British Association of Dermatologists guidelines recommend an SPF30 and either 4 or 5 star UVA protection [<a class=\"bibliography-reference internal-reference\" href=\"/topics/melanoma-pigmented-lesions/references/\">BAD, 2013b</a>], whereas guidance from the National Institute for Health and Care Excellence (NICE) recommends a minimum SPF of 15 and 4 star UVA protection  [<a class=\"bibliography-reference internal-reference\" href=\"/topics/melanoma-pigmented-lesions/references/\">NICE, 2016b</a>] . However, NICE discuss that SPF 15 is sufficient if applied adequately, but to take into account behavioural factors (such as insufficient quantities being applied).</li></ul><h5>Advice on the detection of malignant melanoma</h5><ul><li>This recommendation is based on information on melanoma provided by Cancer Research UK [<a class=\"bibliography-reference internal-reference\" href=\"/topics/melanoma-pigmented-lesions/references/\">Cancer Research UK, 2016b</a>].</li></ul><!-- end field e6482c8c-6e83-4aff-92ef-047afae607a4 --><!-- end item 8d74c016-5481-4b29-8ccc-dc49ea8032fb -->","subChapters":[]}]},{"id":"1ddb2353-ba62-5dd9-a3bf-e28a518ad2ff","slug":"benign-pigmented-lesion","fullItemName":"Benign pigmented lesion","depth":3,"htmlHeader":"<!-- begin field 8b7129bf-4d89-4b69-be98-848ff249ef59 --><h3>How should I manage benign pigmented lesions?</h3><!-- end field 8b7129bf-4d89-4b69-be98-848ff249ef59 -->","summary":null,"htmlStringContent":"<!-- begin item e18a091e-80a4-4ac5-b560-a0258627d922 --><!-- begin field 40c15cbf-0e72-4f71-8980-46582b88e768 --><ul><li><strong>If there is a high degree of confidence that the lesion is benign, </strong>reassure the person. Provide them with information (ideally written) regarding the changes that may subsequently suggest malignant transformation and instruct them to return if any such changes occur or if the lesion continues to cause them concern.</li><li><strong>If there is a low degree of suspicion that the lesion is melanoma </strong>(for example it scores 1 or 2 points on the 7-point checklist), advise the person to monitor the lesion (explaining the features to watch for) and to come back if they notice any changes. Ideally, measurement should be made with photographs and a marker scale and/or ruler. Review after 8 weeks. Alternatively, an in-house referral to a colleague for a second opinion is advised. Ideally this will be a GP or GPSI in Dermatology who is able to review the lesion under a Dermatoscope. </li><li><strong>Give advice on prevention of melanoma.</strong></li></ul><!-- end field 40c15cbf-0e72-4f71-8980-46582b88e768 --><!-- end item e18a091e-80a4-4ac5-b560-a0258627d922 -->","subChapters":[{"id":"5a613c06-1f80-54d7-ba1d-639934a90e78","slug":"basis-for-recommendation-1c0","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field 522b95d4-d746-4a0c-9691-51c3630d283f --><h4>Basis for recommendation</h4><!-- end field 522b95d4-d746-4a0c-9691-51c3630d283f -->","summary":null,"htmlStringContent":"<!-- begin item 1c03dfd1-4f77-4e87-ba08-12edd056016f --><!-- begin field d95bd9be-56dd-42c0-8cae-68618a6be2a7 --><h5>Reassurance</h5><ul><li>This recommendation is based on a guideline from the National Institute for Health and Care Excellence on <em>Improving outcomes for people with skin tumours including melanoma </em>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/melanoma-pigmented-lesions/references/\">NICE, 2006</a>] and guidelines from the Scottish Intercollegiate Guidelines Network on <em>Cutaneous melanoma </em>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/melanoma-pigmented-lesions/references/\">SIGN, 2017</a>].</li></ul><h5>Monitoring</h5><ul><li>This recommendation is based on expert opinion in a guideline from the National Institute for Health and Care Excellence on <em>Referral for suspected cancer </em>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/melanoma-pigmented-lesions/references/\">NICE, 2005</a>] and Melanoma: Summary of NICE Guideline [<a class=\"bibliography-reference internal-reference\" href=\"/topics/melanoma-pigmented-lesions/references/\">Macbeth, 2015</a>]. </li></ul><!-- end field d95bd9be-56dd-42c0-8cae-68618a6be2a7 --><!-- end item 1c03dfd1-4f77-4e87-ba08-12edd056016f -->","subChapters":[]}]}]}}},"staticQueryHashes":["3666801979"]}